Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Tandem Diabetes Care, Inc. (TD5A.F)

15.24
-0.49
(-3.08%)
As of 8:01:16 AM GMT+2. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. John F. Sheridan President, CEO & Director 1.23M -- 1955
Ms. Leigh A. Vosseller Executive VP, CFO & Treasurer 614.48k -- 1973
Mr. Jean-Claude E. Kyrillos Executive VP & COO 474.83k -- 1964
Ms. Susan M. Morrison Executive VP & Chief Administrative Officer 615.26k -- 1979
Ms. Elizabeth Anne Gasser Executive VP and Chief Strategy & Product Officer 615.26k -- 1976
Mr. Mark Novara Executive VP & Chief Commercial Officer 627.76k -- 1975
Mr. Rick A. Carpenter Chief Technical Officer -- -- 1963
Ms. Shannon M. Hansen J.D. Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary -- -- 1966
Mr. Tom Fox Chief Human Resources Officer -- -- --
Dr. Jordan Pinsker M.D. Chief Medical Officer -- -- --

Tandem Diabetes Care, Inc.

12400 High Bluff Drive
San Diego, CA 92130
United States
858 366 6900 https://www.tandemdiabetes.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
2,650

Description

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Corporate Governance

Tandem Diabetes Care, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 3. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 4; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 30, 2025 at 8:00 PM UTC

Tandem Diabetes Care, Inc. Earnings Date

Recent Events